banner
PDGFR inhibitor AB1010, Purity ≥98%
Inquiry

Cat. No.: X24-06-ZQ133

PDGFR inhibitor AB1010, Purity ≥98%

Synonym: 790299-79-5; PDGFR inhibitor; AB1010; Masivet

  • MDL: MFCD09954132
  • CAS Number: 790299-79-5
  • Compound CID: 10074640
img
Product Size
10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
AB1010, soluble in DMSO and ethanol and insoluble in water, blocks the activity of platelet-derived growth factor receptors (PDGFR), which play a crucial role in cell growth, angiogenesis, and tissue. It targets LynB, PDGFRα, Abl1, Akt1, Bmx, BTK, c-Fms, c-Met, c-Ret, EGFR, and Fes.
Molecular Weight
498.6
Molecular Formula
C28H30N6OS
Targets
LynB: 510 nM; PDGFRα: 540 nM; Abl1: 1.20 μM; Akt1: >10 μM; Bmx: >10 μM; BTK: >10 μM; c-Fms; c-Met: >10 μM; c-Ret: >10 μM; EGFR: >10 μM; Fes: >10 μM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 91 mg/mL (182.49 mM); Water: Insoluble; Ethanol: 4 mg/mL
Identity
Confirmed by NMR/HPLC/MS.
Applications
AB1010, or Masitinib, is a PDGFR inhibitor in investigations into cancer therapeutics.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0